Nwam LLC Buys New Stake in VanEck Biotech ETF $BBH

Nwam LLC purchased a new position in VanEck Biotech ETF (NASDAQ:BBH) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 91,586 shares of the company’s stock, valued at approximately $18,614,000. VanEck Biotech ETF comprises 0.9% of Nwam LLC’s investment portfolio, making the stock its 20th largest position. Nwam LLC owned approximately 4.70% of VanEck Biotech ETF at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the business. Northwestern Mutual Wealth Management Co. grew its position in VanEck Biotech ETF by 40,463.3% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 494,061 shares of the company’s stock worth $93,506,000 after acquiring an additional 492,843 shares in the last quarter. Quantitative Investment Management LLC bought a new stake in shares of VanEck Biotech ETF in the 2nd quarter valued at approximately $7,589,000. Ascent Advisors LLC purchased a new position in shares of VanEck Biotech ETF in the 1st quarter worth approximately $11,178,000. Raymond James Financial Inc. increased its position in shares of VanEck Biotech ETF by 245.9% during the 2nd quarter. Raymond James Financial Inc. now owns 67,940 shares of the company’s stock valued at $10,414,000 after purchasing an additional 48,297 shares during the last quarter. Finally, Bank of America Corp DE increased its position in shares of VanEck Biotech ETF by 44.3% during the 1st quarter. Bank of America Corp DE now owns 66,338 shares of the company’s stock valued at $12,473,000 after purchasing an additional 20,375 shares during the last quarter. Institutional investors own 32.05% of the company’s stock.

VanEck Biotech ETF Stock Down 0.4%

NASDAQ BBH opened at $235.50 on Tuesday. The company has a fifty day moving average of $213.87 and a two-hundred day moving average of $197.38. VanEck Biotech ETF has a 52 week low of $160.91 and a 52 week high of $244.35.

Insider Buying and Selling

In related news, major shareholder Sardar Biglari sold 6,533 shares of the company’s stock in a transaction dated Wednesday, July 15th. The shares were sold at an average price of $16.71, for a total transaction of $109,166.43. Following the transaction, the insider directly owned 3,552,710 shares in the company, valued at approximately $59,365,784.10. This represents a 0.18% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last 90 days, insiders have sold 10,493 shares of company stock worth $175,335.

VanEck Biotech ETF Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.